New Journal Website is available at:

Published by: Kowsar

Oral L-Arginine Administration Improves Anthropometric and Biochemical Indices Associated With Cardiovascular Diseases in Obese Patients: A Randomized, Single Blind Placebo Controlled Clinical Trial

Arash Dashtabi 1 , Zohreh Mazloom 1 , * , Mohammad Fararouei 2 and Najmeh Hejazi 3
Authors Information
1 School of Nutrition and Food Science, Shiraz University of Medical Sciences, Shiraz, IR Iran
2 School of Health, Shiraz University of Medical Science, Shiraz, IR Iran
3 Nutrition and Food Science Research Center, School of Nutrition and Food Science, Shiraz University of Medical Sciences, Shiraz, IR Iran
Article information
  • Research in Cardiovascular Medicine: February 2016, 5 (1); e29419
  • Published Online: December 29, 2015
  • Article Type: Research Article
  • Received: April 28, 2015
  • Revised: June 25, 2015
  • Accepted: June 27, 2015
  • DOI: 10.5812/cardiovascmed.29419

To Cite: Dashtabi A, Mazloom Z, Fararouei M, Hejazi N. Oral L-Arginine Administration Improves Anthropometric and Biochemical Indices Associated With Cardiovascular Diseases in Obese Patients: A Randomized, Single Blind Placebo Controlled Clinical Trial, Res Cardiovasc Med. 2016 ;5(1):e29419. doi: 10.5812/cardiovascmed.29419.

Copyright: Copyright © 2016, Research in Cardiovascular Medicine. .
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. Poirier P, Eckel RH. Obesity and cardiovascular disease. Curr Atheroscler Rep. 2002; 4(6): 448-53[PubMed]
  • 2. Media centre Obesity and Overweight. 2009;
  • 3. Pi-Sunyer FX, Becker DM, Bouchard C, Carleton RA, Colditz GA, Dietz WH. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: Executive summary. Am J Clin Nutr. 1998; 68(4): 899-917
  • 4. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004; 364(9438): 937-52[DOI][PubMed]
  • 5. Yusuf S, Vaz M, Pais P. Tackling the challenge of cardiovascular disease burden in developing countries. Am Heart J. 2004; 148(1): 1-4[DOI][PubMed]
  • 6. Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation. 1983; 67(5): 968-77[PubMed]
  • 7. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest. 1995; 95(5): 2409-15[DOI][PubMed]
  • 8. Poirier P, Despres JP. Waist circumference, visceral obesity, and cardiovascular risk. J Cardiopulm Rehabil. 2003; 23(3): 161-9[PubMed]
  • 9. Leslie RDG, Cohen RM. Biologic Variability in Plasma Glucose, Hemoglobin A1c, and Advanced Glycation End Products Associated with Diabetes Complications. J Diabetes Sci Technol. 2009; 3(4): 635-43[DOI]
  • 10. Giardino I, Edelstein D, Brownlee M. BCL-2 expression or antioxidants prevent hyperglycemia-induced formation of intracellular advanced glycation endproducts in bovine endothelial cells. J Clin Invest. 1996; 97(6): 1422-8[DOI][PubMed]
  • 11. Jablecka A, Bogdanski P, Balcer N, Cieslewicz A, Skoluda A, Musialik K. The effect of oral L-arginine supplementation on fasting glucose, HbA1c, nitric oxide and total antioxidant status in diabetic patients with atherosclerotic peripheral arterial disease of lower extremities. Eur Rev Med Pharmacol Sci. 2012; 16(3): 342-50[PubMed]
  • 12. Roberts W, Riba R, Homer-Vanniasinkam S, Farndale RW, Naseem KM. Nitric oxide specifically inhibits integrin-mediated platelet adhesion and spreading on collagen. J Thromb Haemost. 2008; 6(12): 2175-85[DOI][PubMed]
  • 13. Gatto C. NO control: nitric oxide directly regulates substrate delivery to NOS. Focus on "Nitric oxide can acutely modulate its biosynthesis through a negative feedback mechanism on L-arginine transport in cardiac myocytes". Am J Physiol Cell Physiol. 2010; 299(2)-5[DOI][PubMed]
  • 14. Martina V, Masha A, Gigliardi VR, Brocato L, Manzato E, Berchio A, et al. Long-term N-acetylcysteine and L-arginine administration reduces endothelial activation and systolic blood pressure in hypertensive patients with type 2 diabetes. Diabetes Care. 2008; 31(5): 940-4[DOI][PubMed]
  • 15. Bruckdorfer KR, Jacobs M, Rice-Evans C. Endothelium-derived relaxing factor (nitric oxide), lipoprotein oxidation and atherosclerosis. Biochem Soc Trans. 1990; 18(6): 1061-3[PubMed]
  • 16. Piatti PM, Monti LD, Valsecchi G, Magni F, Setola E, Marchesi F, et al. Long-term oral L-arginine administration improves peripheral and hepatic insulin sensitivity in type 2 diabetic patients. Diabetes Care. 2001; 24(5): 875-80[PubMed]
  • 17. Jablecka A, Checinski P, Krauss H, Micker M, Ast J. The influence of two different doses of L-arginine oral supplementation on nitric oxide (NO) concentration and total antioxidant status (TAS) in atherosclerotic patients. Med Sci Monit. 2004; 10(1)-32[PubMed]
  • 18. Boger RH, Bode-Boger SM, Phivthong-ngam L, Brandes RP, Schwedhelm E, Mugge A, et al. Dietary L-arginine and alpha-tocopherol reduce vascular oxidative stress and preserve endothelial function in hypercholesterolemic rabbits via different mechanisms. Atherosclerosis. 1998; 141(1): 31-43[PubMed]
  • 19. Lucotti P, Setola E, Monti LD, Galluccio E, Costa S, Sandoli EP, et al. Beneficial effects of a long-term oral L-arginine treatment added to a hypocaloric diet and exercise training program in obese, insulin-resistant type 2 diabetic patients. Am J Physiol Endocrinol Metab. 2006; 291(5)-12[DOI][PubMed]
  • 20. Saghaei M. Random allocation software for parallel group randomized trials. BMC Med Res Methodol. 2004; 4: 26[DOI][PubMed]
  • 21. Olson NC, Callas PW, Hanley AJ, Festa A, Haffner SM, Wagenknecht LE, et al. Circulating levels of TNF-alpha are associated with impaired glucose tolerance, increased insulin resistance, and ethnicity: the Insulin Resistance Atherosclerosis Study. J Clin Endocrinol Metab. 2012; 97(3): 1032-40[DOI][PubMed]
  • 22. Cartier A, Cote M, Bergeron J, Almeras N, Tremblay A, Lemieux I, et al. Plasma soluble tumour necrosis factor-alpha receptor 2 is elevated in obesity: specific contribution of visceral adiposity. Clin Endocrinol (Oxf). 2010; 72(3): 349-57[DOI][PubMed]
  • 23. Lamarche B, Uffelman KD, Carpentier A, Cohn JS, Steiner G, Barrett PH, et al. Triglyceride enrichment of HDL enhances in vivo metabolic clearance of HDL apo A-I in healthy men. J Clin Invest. 1999; 103(8): 1191-9[DOI][PubMed]
  • 24. Balon TW, Nadler JL. Nitric oxide release is present from incubated skeletal muscle preparations. J Appl Physiol (1985). 1994; 77(6): 2519-21[PubMed]
  • 25. Schneider JG, von Eynatten M, Schiekofer S, Nawroth PP, Dugi KA. Low plasma adiponectin levels are associated with increased hepatic lipase activity in vivo. Diabetes Care. 2005; 28(9): 2181-6[PubMed]
  • 26. Ast J, Jabłecka A, Bogdański P, Smolarek I, Krauss H, Chmara E, et al. Evaluation of antihypertensive effect of l-arginine supplementation in patients with mild hypertension assessed with ambulatory blood pressure monitoring. Pharmacol Rep. 2010; 62: 73[DOI]
  • 27. Schlaich MP, Parnell MM, Ahlers BA, Finch S, Marshall T, Zhang WZ, et al. Impaired L-arginine transport and endothelial function in hypertensive and genetically predisposed normotensive subjects. Circulation. 2004; 110(24): 3680-6[DOI][PubMed]
  • 28. Khaw KT, Wareham N, Luben R, Bingham S, Oakes S, Welch A, et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of european prospective investigation of cancer and nutrition (EPIC-Norfolk). BMJ. 2001; 322(7277): 15-8[PubMed]
  • 29. Young ME, Leighton B. Evidence for altered sensitivity of the nitric oxide/cGMP signalling cascade in insulin-resistant skeletal muscle. Biochem J. 1998; 329 ( Pt 1): 73-9[PubMed]
  • 30. Cooke JP. Does ADMA cause endothelial dysfunction? Arterioscler Thromb Vasc Biol. 2000; 20(9): 2032-7[PubMed]
  • 31. Maxwell AJ, Anderson BE, Cooke JP. Nutritional therapy for peripheral arterial disease: a double-blind, placebo-controlled, randomized trial of HeartBar. Vasc Med. 2000; 5(1): 11-9[PubMed]
  • 32. Lubec B, Hayn M, Kitzmuller E, Vierhapper H, Lubec G. L-Arginine reduces lipid peroxidation in patients with diabetes mellitus. Free Radic Biol Med. 1997; 22(1-2): 355-7[PubMed]
  • 33. Lantos J, Roth E, Czopf L, Nemes J, Gal I. Monitoring of plasma total antioxidant status in different diseases. Acta Chir Hung. 1997; 36(1-4): 188-9[PubMed]
  • 34. Gutteridge JM. Lipid peroxidation and antioxidants as biomarkers of tissue damage. Clin Chem. 1995; 41(12 Pt 2): 1819-28[PubMed]
  • 35. Santillo M, Mondola P, Milone A, Gioielli A, Bifulco M. Ascorbate administration to normal and cholesterol-fed rats inhibits in vitro TBARS formation in serum and liver homogenates. Life Sci. 1996; 58(14): 1101-8[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader